Last updated: 11/07/2018 08:29:45
A Companion Glucose-6-phosphate dehydrogenase (G6PD) enzyme assay validation protocol to the study TAF110027
GSK study ID
115016
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Companion Glucose-6-phosphate dehydrogenase (G6PD) enzyme assay validation protocol to the study TAF110027
Trial description: A Companion Glucose-6-phosphate dehydrogenase (G6PD) enzyme assay validation protocol to the study TAF110027
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Rueangweerayut R, Bancone G, Harrell E, Beelen A, Kongpatanakul S, Moehrle J, Roussell V, Mohamed K, Qureshi A, Narayan S, Yubon N, Miller A, Nosten F, Luzzatto L, Duparc S, Kleim JP, Green J. Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency (Mahidol Variant) versus G6PD-normal Volunteers. Am J Trop Med Hyg. 2017;7(3):702-711
Medical condition
Malaria
Product
tafenoquine
Collaborators
Not applicable
Study date(s)
January 2011 to April 2011
Type
Not applicable
Phase
1
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2011-04-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website